MyFiziq teams up with Evolt to launch new age app
MyFiziq Limited (ASX: MYQ) has provided an update on the release of the Evolt360 application which is now available in the Apple App store.
Evolt is an FDA approved medical grade device/machine-based intelligent body scanning technology purchased and supported by health, fitness, and wellness companies including but not limited to F45, Anytime Fitness, HCF and KPMG.
These companies and many more are looking to provide greater insight into the health of their members and employees.
The scans performed by the technology are made available to consumers for between $30 and $50 per scan depending on the type of scan performed and level of membership.
Evolt has released the much anticipated Evolt360 application with in-app body scanning using the MyFiziq technology.
The MyFiziq technology is intended to extend the Evolt reach into the hands of their 500,000 consumers at home.
With the new integration, customers of Evolt will be able to download access to the MyFiziq technology, via the Evolt app, which is available in the Apple App Store.
The Evolt application with the MyFiziq in-app scanning capability is being released on iOS initially, with Android to follow.
In addition to the body tracking capabilities, Evolt will be embedding its biometric data into the machine learning data with MyFiziq within the application, delivering a broader data set than has been made available in any application of its kind to date.
Tracks quality of activity, body composition and nutrition
Evolt has developed a unique end-to-end solution that tracks detailed changes in the quality of the activity, body composition and nutrition, as well as sophisticated data analytics for its user’s body changes.
With the added functionality of tracking circumference change as an additional data set, Evolt is inspiring and educating its users with real-time data to drive and assist in the delivery of personal goals.
In just a few short years, Evolt has become a global player, securing contracts across multiple verticals, from health insurers, health, and fitness retailers to government bodies and some of the world’s largest gym chains.
Targeting robust revenues in first 12 months
Highlighting the potential revenue generation from incorporating Evolt into MyFiziq’s product offering, chief executive Vlado Bosanac said, “The launch of Evolt has been much awaited both by MyFiziq and our shareholders.
"Evolt has committed to targeting an initial 100,000 active users onto the joint offering in the first 12 months and MyFiziq will receive $2.99 per month per user. This will mark the release of our second consumer application.
"If the initial target user numbers are achieved, it would see the Company meet an initial break-even position, based on current monthly burn. The application has been through rigorous testing in readiness for this launch. I am pleased to say the application is performing well on all fronts. The look and feel of the application is a credit to both teams. We are looking forward to supporting Evolt with its launch, users, downloads, and usage. As Evolt has been granted an FDA medical device approval, we believe this will bring a great deal of interest to both companies as we co-promote this unique and comprehensive capability to multiple business verticals, both current and new.
"The FDA medical device approval held by Evolt is of particular benefit to both companies as we share a common interest in distributing the solution to governments, medical organisations, and insurers. The FDA approval brings validity to the device and its functionality is often required in such organisations, when looking to use the device as part of a decision-making process rather than a monitoring device.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.